Xpert® MTB/RIF Ultra
Enhanced performance in detecting drug-sensitive and -resistant Tuberculosis in less than 80 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
50 Tests
GXMTB/RIF-ULTRA-50
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
product image
10 Tests
GXMTB/RIF-ULTRA-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support

The Need

  • Each day, close to 4,400 people lose their lives to TB and nearly 30,000 people fall ill with this preventable and curable disease1
  • Globally, diagnosis of TB and drug-resistant TB remains a challenge, with a third of people with TB and two-thirds of people with drug-resistant TB not being detected1
  • Precise and early detection of TB is needed to improve case management and significantly enhance the prevention of TB transmission2
1 World Health Organization Tuberculosis Report 2023 - https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023
2 Centers for Disease Control and Prevention—Guidelines for preventing the transmission of TB - https://www.cdc.gov/mmwr/preview/mmwrhtml/00001897.htm

The Solution

  • Xpert MTB/RIF Ultra provides fast and highly accurate detection of Mycobacterium Tuberculosis (MTB) and Rifampicin (RIF) resistance simultaneously from patient samples
  • Higher sensitivity, especially in smear-negative TB cases and among HIV-infected patients3
  • Simple three-step process with minimal hands-on time and results in ~80 min direct from sample
  • Designed to provide the most accurate MTB and Rifampicin detection utilizing multi-target and melt curves technology
  • Accurate detection of mixed infections
3 Aliasgar Esmail, et al, Comparison of Xpert MTB/RIF (G4) and Xpert Ultra, including trace readouts, for the diagnosis of pulmonary tuberculosis in a TB and HIV endemicsetting https://researchonline.lshtm.ac.uk/id/eprint/4661245/1/1-s2.0-S1201971220301442-main.pdf

The Impact

  • Early detection of MTB and resistance to Rifampicin enables faster access to the most appropriate treatment for better patient outcomes4
  • Increased access to front-line testing with Xpert MTB/RIF Ultra as part of active case finding and management can help limit community transmission5
  • Superior performance of Xpert MTB/RIF Ultra versus smear microscopy enables more people with MTB infections to be detected and treated earlier4
4 Charkravorty S, et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing - https://journals.asm.org/doi/10.1128/mbio.00812-17
5 Belén Saavedra, et al. Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding - https://erj.ersjournals.com/content/58/6/2100257